Nurix pens $2.3bn collaboration with Gilead; Option exercised
Nurix Therapeutics Inc. gained another major partner through a new multi-year deal with Gilead Sciences Inc. in which the companies will focus on targeted protein degradation treatments for cancer and other serious diseases.
- Drug Discovery Technologies
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.